Kajian Interaksi Obat Potensial di Ruang Rawat Jantung Salah Satu Rumah Sakit di Manado: Studi Retrospektif
DOI:
https://doi.org/10.35799/pha.14.2025.61840Keywords:
potensi interaksi obat, penyakit jantung, Rumah SakitAbstract
Penggunaan kombinasi obat pada pasien jantung dapat meningkatkan resiko kejadian interaksi obat. Interaksi obat termasuk salah satu masalah terkait obat yang mengakibatkan kerugian pada pasien. Penelitian ini bertujuan untuk mengidentifikasi kombinasi obat yang berpotensi menyebabkan interaksi serta menganalisis tingkat risiko klinis interaksi obat pada pasien penyakit jantung. Studi observasional retrospektif ini dilakukan di Instalasi Rawat Inap Cardiovascular and Brain Center (CVBC) salah satu rumah sakit di Manado selama Januari hingga Maret 2020. Data dikumpulkan dari rekam medik dan rekonsiliasi obat 49 pasien. Hasil menunjukkan bahwa 100% pasien mengalami interaksi obat potensial selama dirawat inap, 98% saat keluar dari rumah sakit, dan 53,1% saat di IGD. Lansoprazol, atorvastatin, klopidogrel, dan aspirin merupakan obat yang paling sering digunakan, serta paling sering terlibat dalam interaksi. Jenis interaksi yang dominan adalah farmakodinamik (69,1%) saat rawat inap dan farmakokinetik (46,3%) saat di IGD. Sebagian besar interaksi dikategorikan dengan tingkat keparahan moderat. Kombinasi lansoprazol + atorvastatin, lansoprazol + klopidogrel, dan aspirin + klopidogrel termasuk dalam interaksi yang paling sering terjadi. Temuan ini menekankan pentingnya pemantauan ketat terhadap potensi interaksi obat pada pasien penyakit jantung guna mencegah dampak klinis yang merugikan dan meningkatkan keamanan terapi. Penelitian ini merekomendasikan keterlibatan farmasis klinis secara aktif dalam proses peresepan dan rekonsiliasi obat.
References
World Health Organization. (2021). Cardiovascular diseases (CVDs). Diakses dari https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Balitbangkes RI. (2018). Laporan Riskesdas 2018 Nasional.pdf. In Lembaga Penerbit Balitbangkes.
Ma, T.T, Wong, I.C.K., Man, K.K.C., Chen, Y., Crake, T., Ozkor, M.A., Ding, L.Q., Wang, Z.X., Zhang, L., Wei, L. (2019) Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis. PLoS ONE 14(1): e0210988. https://doi.org/10.1371/journal.pone.0210988
Rea, F., Corrao, G., Merlino, L., & Mancia, G. (2018). Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. European Heart Journal, 39, 3654–3661. https://doi.org/10.1093/eurheartj/ehy420.
Akbar, Z., Rehman, S., Khan, A., Khan, A., Atif, M., & Ahmad, N. (2021). Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study. Journal of Pharmaceutical Policy and Practice, 14, 63. https://doi.org/10.1186/s40545-021-00348-1.
Murtaza, G., Khan, M., Azhar, S., Khan, S., & Khan, T. (2015). Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharmaceutical Journal : SPJ, 24, 220 - 225. https://doi.org/10.1016/j.jsps.2015.03.009.
Sahoo A.K, Singh A., Gupta D., Dhaneria S., Arunima P. (2024). Assessment of Potential Drug-drug Interactions (pDDIs) and Their Risk Factors Among Hospitalized Cardiac Patients in a Tertiary-care Center of Central India: A Retrospective Record-based Study. Hospital Pharmacy. 59 (1): 24-31. doi:10.1177/00185787231182569
Khaled, A., Almaghaslah, D., Nagib, R., Makki, S., & Shafique, A. (2023). Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.. European review for medical and pharmacological sciences, 27 (2): 737-743 . https://doi.org/10.26355/eurrev_202301_31076.
Arwa, Khaled., D, Almaghaslah., Reem, Nagib., Soha, Makki., Abu, Md, Shafique. (2023). Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.. European Review for Medical and Pharmacological Sciences, 27 2(2):737-743. doi: 10.26355/eurrev_202301_31076
Ana, Pejčić., Slobodan, M., Jankovic., Goran, Davidovic. (2019). Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review. Serbian Journal of Experimental and Clinical Research, -1 doi: 10.2478/SJECR-2019-0070
Mateti, U., Rajakannan, T., Nekkanti, H., Rajesh, V., Mallaysamy, S., & Ramachandran, P. (2011). Drug-drug interactions in hospitalized cardiac patients. Journal of young pharmacists : JYP, 3(4), 329–333. https://doi.org/10.4103/0975-1483.90246
Macek, P., Żak, M., Terek-Derszniak, M., Biskup, M., Ciepiela, P., Król, H., Smok-Kalwat, J., & Góźdź, S. (2020). Age-Dependent Disparities in the Prevalence of Single and Clustering Cardiovascular Risk Factors: A Cross-Sectional Cohort Study in Middle-Aged and Older Adults. Clinical Interventions in Aging, 15: 161 - 169. https://doi.org/10.2147/CIA.S238930.
Bae, S., Kim, S., Kim, M., Shim, W., & Park, S. (2020). Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart, 107:373-380. https://doi.org/10.1136/heartjnl-2020-317901.
Lettino, M., Mascherbauer, J., Nordaby, M., Ziegler, A., Collet, J., Derumeaux, G., Hohnloser, S., Leclercq, C., O’Neill, D., Visseren, F., Weidinger, F., & Richard-Lordereau, I. (2022). Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table.. European journal of preventive cardiology, 29(10):1412–1424. https://doi.org/10.1093/eurjpc/zwac033.
Alhumaidi, Reham M., Ghazi A. Bamagous, Safaa M. Alsanosi, Hamsah S. Alqashqari, Rawabi S. Qadhi, Yosra Z. Alhindi, Nahla Ayoub, and Alaa H. Falemban. 2023. "Risk of Polypharmacy and Its Outcome in Terms of Drug Interaction in an Elderly Population: A Retrospective Cross-Sectional Study" Journal of Clinical Medicine 12, no. 12: 3960. https://doi.org/10.3390/jcm12123960
Benjamin, E. J., Muntner, P., Alonso, A., et al. (2019). Heart Disease and Stroke Statistics—2019 Update. Circulation, 139(10), e56–e528. https://doi.org/10.1161/CIR.0000000000000659
Jain, S., Jain, P., Sharma, K., & Saraswat, P. (2017). A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit.. Journal of clinical and diagnostic research : JCDR, 11 3, FC01-FC04 . https://doi.org/10.7860/JCDR/2017/23638.9403.
Beers, M., Storrie, M., & Lee, G. (2020). Potential adverse drug interactions in the emergency room. An issue in the quality of care.. Annals of internal medicine, 112 1, 61-4 . https://doi.org/10.7326/0003-4819-112-1-61.
Akbar, Z., Rehman, S., Khan, A., Khan, A., Atif, M., & Ahmad, N. (2021). Potential drug–drug interactions in patients with cardiovascular diseases: findings from a prospective observational study. Journal of Pharmaceutical Policy and Practice, 14. https://doi.org/10.1186/s40545-021-00348-1.
Khaled, A., Almaghaslah, D., Nagib, R., Makki, S., & Shafique, A. (2023). Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.. European review for medical and pharmacological sciences, 27 2, 737-743 . https://doi.org/10.26355/eurrev_202301_31076.
Al-Jabi, S., Aldabe, L., Alhaj-Asaad, L., Thaher, M., Zyoud, S., & Sweileh, W. (2021). Assessment of drug interactions and their associated factors among patients with cardiovascular diseases: a cross-sectional study from the occupied Palestinian territory. The Lancet, 398. https://doi.org/10.1016/S0140-6736(21)01494-X.
Sultana, D., Singh, M., Kumar, A., Kumar, R., Saha, P., Kumar, R., & Kumar, D. (2022). To Identify Drug-Drug Interaction in Cardiac Patients in Tertiary Care Hospitals. Journal for Research in Applied Sciences and Biotechnology. https://doi.org/10.55544/jrasb.1.3.20.
Murtaza, G., Khan, M., Azhar, S., Khan, S., & Khan, T. (2015). Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharmaceutical Journal : SPJ, 24, 220 - 225. https://doi.org/10.1016/j.jsps.2015.03.009.
Guo, H., Ye, Z., & Huang, R. (2021). Clinical Outcomes of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.694698.
Liang, S., , M., Chen, Y., Zhang, J., Li, J., Jiang, S., Wang, Y., Huang, H., & He, Y. (2023). The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, 24. https://doi.org/10.31083/j.rcm2408230.
Luo, X., Hou, M., He, S., Yang, X., Zhang, P., Zhao, Y., & Xing, H. (2023). Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1021584.
Ohbuchi, M., Noguchi, K., Kawamura, A., & Usui, T. (2012). Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica, 42, 633 - 640. https://doi.org/10.3109/00498254.2011.653655.
Ogilvie, B., Yerino, P., Kazmi, F., Buckley, D., Rostami-Hodjegan, A., Paris, B., Toren, P., & Parkinson, A. (2011). The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metabolism and Disposition, 39, 2020 - 2033. https://doi.org/10.1124/dmd.111.041293.
Frelinger, A., Lee, R., Mulford, D., Wu, J., Nudurupati, S., Nigam, A., Brooks, J., Bhatt, D., & Michelson, A. (2012). A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.. Journal of the American College of Cardiology, 59 14, 1304-11 . https://doi.org/10.1016/j.jacc.2011.12.024.
Pravesh Kumar Bundhun, Abhishek Rishikesh Teeluck, Akash Bhurtu, & Huang, W.-Q. (2017). Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 – 2016). BMC Cardiovascular Disorders, 17(1). https://doi.org/10.1186/s12872-016-0453-6
Khan, M. Y., Ponde, C. K., Kumar, V., & Gaurav, K. (2022). Fondaparinux: A cornerstone drug in acute coronary syndromes. World journal of cardiology, 14(1), 40–53. https://doi.org/10.4330/wjc.v14.i1.40
Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Ogita, M., Suwa, S., Isawa, T., Domei, T., Yamaji, K., Tatsushima, S., Watanabe, H., Ohya, M., Tokuyama, H., Tada, T., Sakamoto, H., Mori, H., Suzuki, H., Nishikura, T., Wakabayashi, K., Hibi, K., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Morino, Y., Kadota, K., Furukawa, Y., Nakagawa, Y., & Kimura, T. (2022). Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.. JAMA cardiology. https://doi.org/10.1001/jamacardio.2021.5244.
Puspitasari, A. D., Salean, D. D. C., Hasmono, D., Hartono, R., & Ardiana, M. (2021). A study of anticoagulant therapy in patients with coronary artery disease. Journal of basic and clinical physiology and pharmacology, 32(4), 473–478. https://doi.org/10.1515/jbcpp-2020-0486
Ai, M., Chen, Y., Kuo, C., & Chang, W. (2024). A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1385318.
Harris, J., Pouwels, K., Johnson, T., Sterne, J., Pithara, C., Mahadevan, K., Reeves, B., Benedetto, U., Loke, Y., Lasserson, D., Doble, B., Hopewell-Kelly, N., Redwood, S., Wordsworth, S., Mumford, A., Rogers, C., & Pufulete, M. (2023). Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.. Health technology assessment, 27 8, 1-257 . https://doi.org/10.3310/MNJY9014.
Pantuzza, L., Ceccato, M., Silveira, M., Junqueira, L., & Reis, A. (2017). Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. European Journal of Clinical Pharmacology, 73, 1475 - 1489. https://doi.org/10.1007/s00228-017-2315-2.
Muylle, K., Gentens, K., Dupont, A., & Cornu, P. (2021). Evaluation of an optimized context-aware clinical decision support system for drug-drug interaction screening. International journal of medical informatics, 148, 104393 . https://doi.org/10.1016/j.ijmedinf.2021.104393.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Meilani Jayanti, Utami Sasmita Lestari, Sri Sudewi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
